Join us for a Peer Discussion about treating metastatic colorectal cancer.

Metastatic Colorectal Cancer

CYRAMZA, in combination with FOLFIRI (irinotecan, folinic acid, and fluorouracil), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

SELECT IMPORTANT SAFETY INFORMATION

HEMORRHAGE

  • CYRAMZA increased the risk of hemorrhage and gastrointestinal hemorrhage, including Grade ≥3 hemorrhagic events. Across five clinical studies in 1916 patients with various cancers treated with CYRAMZA, the incidence of all Grade hemorrhage occurred between 13-44%. Grade 3-5 hemorrhage incidence ranged from 2-5%.
  • Permanently discontinue CYRAMZA in patients who experience severe (Grade 3 or 4) bleeding.

SELECT A SPEAKER TO VIEW THEIR BIO

Ari D. Baron, MD

Putao Cen, MD

Minsig Choi, MD

Richard D. Kim, MD

Damian A. Laber, MD, FACP

Benjamin A. Weinberg, MD

AVAILABLE TOPICS

Molecular and Clinical Considerations
in mCRC

Discuss important molecular and clinical characteristics to consider when making treatment decisions for patients with mCRC. Take an in-depth look at the role of antiangiogenic therapies and review future considerations for treating patients with mCRC.

Meet Diane: A Patient With KRAS Mutant mCRC Who Rapidly Progressed on First-Line Therapy

Review a clinical case presentation of a hypothetical patient with KRAS mutant mCRC who rapidly progressed on first-line bevacizumab + mFOLFOX6, including symptoms at presentation, medical and social history, and patient goals. Discuss why CYRAMZA may be an appropriate option for this patient.

Treating mCRC After Disease Progression

Review key efficacy and safety data from the pivotal phase III RAISE trial, which studied CYRAMZA in combination with FOLFIRI in patients with mCRC who progressed on or after prior treatment with bevacizumab, oxaliplatin, and a fluoropyrimidine.

PLEASE SELECT YOUR DESIRED TOPIC AND SPEAKER